These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 6878375)

  • 21. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage.
    Karn KE; Ogburn PL; Julian T; Cerra FB; Hammerschmidt DE; Vercellotti G
    Obstet Gynecol; 1985 Jan; 65(1):127-30. PubMed ID: 3871250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perfluorochemicals: artificial blood.
    Smith S
    Dimens Crit Care Nurs; 1984; 3(4):198-206. PubMed ID: 6563996
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.
    Marelli TR
    Crit Care Nurse; 1994 Feb; 14(1):31-8. PubMed ID: 8194324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
    Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
    J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of Fluosol-DA on pulmonary vessels.
    Nishimura N; Sugi T; Hiranuma N
    Prog Clin Biol Res; 1983; 122():283-9. PubMed ID: 6878371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

  • 28. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 29. Influence of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man.
    Fukushima K; Nakamura M; Hinuma K
    Prog Clin Biol Res; 1983; 122():291-8. PubMed ID: 6878373
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluorocarbons and the microcirculation.
    Faithfull NS; Fennema M; Van Alphen WA; Smith AR; Erdmann W; Essed CE; Kok A; Lapin R
    Acta Anaesthesiol Belg; 1984; 35 Suppl():69-78. PubMed ID: 6516761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Success in the radical resection of esophageal cancer with artificial blood infusion: case report.
    Mitsuno T; Kawa Y; Kita A; Kohno N
    Int Surg; 1981; 66(4):355-8. PubMed ID: 7345051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent studies on perfluorochemical (PFC) emulsion as an oxygen carrier in Japan.
    Mitsuno T; Ohyanagi H; Yokoyama K; Suyama T
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):365-73. PubMed ID: 3052644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental studies on fluosol DA administration in acute pancreatitis.
    Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental studies on the possible combined chemotherapy to neoplasms with Fluosol-DA infusion.
    Ohyanagi H; Nishijima M; Usami M; Nishimatsu S; Matsui E; Saitoh Y
    Prog Clin Biol Res; 1983; 122():315-20. PubMed ID: 6576383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of a 35% fluorocarbon emulsion.
    Gould SA; Sehgal LR; Rosen AL; Langdale LA; Sehgal HL; Krause L; Moss GS
    J Trauma; 1983 Aug; 23(8):720-4. PubMed ID: 6887290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
    Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
    Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Fluosol-DA (20%) on skin flap survival in rats.
    Ramasastry SS; Waterman P; Angel MF; Futrell JW
    Ann Plast Surg; 1985 Nov; 15(5):436-42. PubMed ID: 4083744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The place for using erythrocyte substitutes in hemodilution: fluosol-DA and polymerized pyridoxylated hemoglobin].
    Vigneron C; Labrude P; Dellacherie E
    Ann Fr Anesth Reanim; 1986; 5(3):260-8. PubMed ID: 3535579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perfluorocarbon-based oxygen carriers: review of products and trials.
    Castro CI; Briceno JC
    Artif Organs; 2010 Aug; 34(8):622-34. PubMed ID: 20698841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). Part II: Human cerebral blood flow.
    Nagasawa S; Handa H; Yonekawa Y; Oda Y; Tsuda Y; Yokoyama K
    Neurol Res; 1983; 5(2):19-30. PubMed ID: 6140661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.